BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » induced pluripotent stem cell

Non-Commercial Organizations Developing iPSC Therapies

July 16, 2019 By Cade Hildreth (CEO) Leave a Comment

iPSC therapies academic and government

There are diverse and ever-growing number of commercial entities supporting the development of induced pluripotent stem cell (iPSC) therapies. However, there are also government and academic entities who are pursuing therapeutic progress with the cell type.

The most notable institutions working toward this goal are:

  1. RIKEN Center in Kobe, Japan
  2. Kyoto University in Kyoto, Japan
  3. California Institute for Regenerative Medicine (CIRM) in California, USA

Each of these important institutions and their contributions to the development of new iPSC therapies is presented below.
[Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: California Institute for Regenerative Medicine, CIRM, induced pluripotent stem cell, iPSC, iPSC therapies, Kyoto University, RIKEN Center

Deal-Making within the Induced Pluripotent Stem Cell (iPS Cell) Industry

August 18, 2015 By Cade Hildreth (CEO) Leave a Comment

PROOF THAT DEAL-MAKING IS ALIVE WITHIN THE INDUCED PLURIPOTENT STEM CELL MARKETPLACE

In this post, we explore seven momentous partnerships that have been formed for purposes of strengthening company dominance within the induced pluripotent stem cell (iPS cell or iPSC) industry.  As you’ll discover, a major theme among the “power players” within the iPSC marketplace is non-exclusive agreements with iPS Academia Japan.

These non-exclusive agreements allow companies access to an absolutely critical iPSC patent portfolio by granting access to the patented discoveries of Dr. Shinya Yamanaka, the scientist who invented induced pluripotent stem cells in 2006.

[Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: ArunA Biomedical, CeeTox, Cellular Dynamics International, EMD Millipore, Fujifilm Holdings, induced pluripotent stem cell, iPSC, Life Technologies, Lonza Group AG, Roslin Cells, Sigma Aldrich

Induced Pluripotent Stem Cell News Round-Up | July 2015

August 12, 2015 By Cade Hildreth (CEO) Leave a Comment

Induced pluripotent stem cells (iPSCs) represent a rapidly evolving area of stem cell science. Since the discovery of the cell type in 2006, there have been several important market events, including the first ever clinical trial in humans which launched in August of 2013 to evaluate the capacity of iPSC-derived cell sheets for their ability to restore vision in patients with wet-type macular degeneration. While this trial has since been paused due to safety concerns, it represents a major milestone in clinical progress with iPSCs.

In another recent event that reverberated throughout the stem cell research community, the Supreme Court rejected the right of the Wisconsin Alumni Research Foundation (WARF) to control patents related to iPSC derivation in a landmark patent decision issued February 2015.

Indeed, every month there are major events occurring in the iPSC sector that shift industry dynamics. Read on to get informed about the most important iPSC market events that occurred in July of 2015.  [Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: current events, induced pluripotent stem cell, industry news, iPS cells, iPSC, iPSC market, news round up

Induced Pluripotent Stem Cell News Round-Up| June 2015

June 24, 2015 By Cade Hildreth (CEO) Leave a Comment

iPSC June News Round Up

Induced pluripotent stem cells (iPSCs) are a rapidly evolving area of stem cell science. Since the discovery of the cell type in 2006, there have been several important market events, including the first ever clinical trial in humans which launched in August of 2013 to evaluate the capacity of iPSC-derived cell sheets for their ability to restore vision in patients with wet-type macular degeneration. More recently, the Supreme Court rejected the right of the Wisconsin Alumni Research Foundation (WARF) to control patents related to iPSC derivation in a landmark patent decision issued in February 2015.

Every month there are major events occurring in the iPSC sector that shift industry dynamics. Read on to get informed about the most important iPSC market events as of June 2015.  [Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: DefiniGEN, episomal reprogramming, Horizon Discovery Group, induced pluripotent stem cell, insulin resistance, iPSC

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.